CEO Alessandro Maselli was paid $6,583,672 in fiscal year 2023, ↑ up 103.6% from fiscal year 2022, the 1st percentile of its disclosed peer group (SEC filing 0001193125-23-295996 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$6,583,672 ↑ Alessandro Maselli total, FY2023 | 1st CEO pay percentile vs peers | — CEO-to-median pay ratio | 97.01% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Alessandro Maselli | $925,000 | $0 | $3,850,216 | $1,650,019 | $0 | $0 | $158,437 | $6,583,672 |
| President and Chief Executive Officer | ||||||||
| John Chiminski | 700,000 | 0 | 4,000,069 | 0 | 0 | 0 | 107,698 | 4,807,767 |
| Former Executive Chair | ||||||||
| Manja Boerman | 511,387 | 0 | 2,455,217 | 195,022 | 0 | 0 | 818,262 | 3,979,888 |
| Former President, Division Head for Biomodalities | ||||||||
| Aristippos Gennadios | 600,000 | 0 | 2,700,277 | 300,017 | 135,000 | 0 | 64,263 | 3,799,557 |
| Group President, Pharma and Consumer Health | ||||||||
| Thomas Castellano | 443,654 | 0 | 875,098 | 375,003 | 0 | 0 | 1,036,228 | 2,729,983 |
| Former Senior Vice President and Chief Financial Officer | ||||||||
| Steven Fasman | 625,000 | 0 | 1,050,221 | 450,025 | 135,000 | 0 | 50,053 | 2,310,299 |
| Former Executive Vice President & Chief Administrative Officer | ||||||||
| Ricky Hopson | 380,000 | 0 | 245,150 | 105,032 | 139,500 | 0 | 102,625 | 972,307 |
| President, Division Head for Clinical Development & Supply and Former Interim Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Alessandro Maselli | $6,583,672 | $3,234,030 | $4,559,730 | ↑ +3,349,642 |
| John Chiminski | 4,807,767 | 12,407,517 | 12,581,139 | ↓ −7,599,750 |
| Manja Boerman | 3,979,888 | — | — | — |
| Aristippos Gennadios | 3,799,557 | 2,125,504 | — | ↑ +1,674,053 |
| Thomas Castellano | 2,729,983 | 1,671,067 | 1,778,546 | ↑ +1,058,916 |
| Steven Fasman | 2,310,299 | 2,799,523 | 2,317,605 | ↓ −489,224 |
| Ricky Hopson | 972,307 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Catalent's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper CTLT reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name CTLT as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2023 total |
|---|---|---|
| Christa Kreuzburg | Independent Director | $375,105 |
| Donald E. Morel Jr | Independent Director | $384,954 |
| Frank A. D'Amelio | Director | — |
| Gregory T. Lucier | Independent Director | $387,605 |
| J. Martin Carroll | Independent Director | $426,355 |
| Jack Stahl | Lead Independent Director | $395,105 |
| John J. Greisch | Chair of the Board | $400,861 |
| Karen Flynn | Director | $357,258 |
| Madhavan Balachandran | Independent Director | $374,954 |
| Michael J. Barber | Independent Director | $374,954 |
| Michelle R. Ryan | Independent Director | — |
| Peter Zippelius | Former director (through FY2023) | $333,565 |
| Rolf Classon | Independent Director | $384,954 |
| Rosemary A. Crane | Independent Director | $384,954 |
| Stephanie Okey | Independent Director | — |
| Steven K. Barg | Independent Director | — |
Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Michael Hatzfeld | Chief Accounting Officer | 2024-01-16 | A | 3,981 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Hatzfeld | Chief Accounting Officer | 2024-01-16 | A | 6,071 | 0 | 0 | Common | Form 4 ↗ |
| Michael Hatzfeld | Chief Accounting Officer | 2024-01-16 | A | 1,837 | 0 | 0 | Common | Form 4 ↗ |
| Christa Kreuzburg | Director | 2024-01-25 | D | 523 | 50 | 26,364 | Common | Form 4 ↗ |
| Scott Gunther | SVP, Quality & Reg. Affairs | 2024-03-15 | D | 387 | 56 | 21,749 | Common | Form 4 ↗ |
| Ricky Hopson | Pres. BioProduct Delivery, CoS | 2024-06-04 | D | 1,401 | 54 | 76,023 | Common | Form 4 ↗ |
| Matti Masanovich | SVP, Chief Financial Officer | 2024-07-08 | D | 2,993 | 57 | 169,823 | Common | Form 4 ↗ |
| Ricky Hopson | Pres. BioProduct Delivery, CoS | 2024-07-26 | A | 10,225 | 0 | 0 | Common | Form 4 ↗ |
| Aristippos Gennadios | Group Pres. Pharma & Consumer | 2024-07-26 | A | 18,746 | 0 | 0 | Common | Form 4 ↗ |
| Alessandro Maselli | Director | 2024-07-26 | A | 98,671 | 0 | 0 | Common | Form 4 ↗ |
| Scott Gunther | SVP, Quality & Reg. Affairs | 2024-07-26 | A | 11,078 | 0 | 0 | Common | Form 4 ↗ |
| Matti Masanovich | SVP, Chief Financial Officer | 2024-07-26 | A | 42,604 | 0 | 0 | Common | Form 4 ↗ |
| Lisa Evoli | SVP, Chief HR Officer | 2024-07-26 | A | 15,338 | 0 | 0 | Common | Form 4 ↗ |
| Joseph Anthony Ferraro | SVP, General Counsel, CCO | 2024-07-26 | A | 17,042 | 0 | 0 | Common | Form 4 ↗ |
| David McErlane | Group President, Biologics | 2024-07-26 | A | 18,746 | 0 | 0 | Common | Form 4 ↗ |
| Michael Hatzfeld | Chief Accounting Officer | 2024-07-26 | A | 5,624 | 0 | 0 | Common | Form 4 ↗ |
| John J. Greisch | Director | 2024-07-26 | A | 63,736 | 0 | 0 | Common | Form 4 ↗ |
| Ricky Hopson | Pres. BioProduct Delivery, CoS | 2024-07-29 | D | 206 | 59 | 12,086 | Common | Form 4 ↗ |
| Aristippos Gennadios | Group Pres. Pharma & Consumer | 2024-07-29 | D | 349 | 59 | 20,486 | Common | Form 4 ↗ |
| Alessandro Maselli | Director | 2024-07-29 | D | 9,088 | 59 | 534,011 | Common | Form 4 ↗ |
| Scott Gunther | SVP, Quality & Reg. Affairs | 2024-07-29 | D | 283 | 59 | 16,609 | Common | Form 4 ↗ |
| Ricky Hopson | Pres. BioProduct Delivery, CoS | 2024-08-02 | D | 662 | 60 | 39,429 | Common | Form 4 ↗ |
| Aristippos Gennadios | Group Pres. Pharma & Consumer | 2024-08-02 | D | 1,169 | 60 | 69,614 | Common | Form 4 ↗ |
| Lisa Evoli | SVP, Chief HR Officer | 2024-08-02 | D | 3,859 | 60 | 230,267 | Common | Form 4 ↗ |
| Joseph Anthony Ferraro | SVP, General Counsel, CCO | 2024-08-02 | D | 608 | 60 | 36,225 | Common | Form 4 ↗ |
| Scott Gunther | SVP, Quality & Reg. Affairs | 2024-08-02 | D | 666 | 60 | 39,660 | Common | Form 4 ↗ |
| David McErlane | Group President, Biologics | 2024-09-26 | D | 1,994 | 60 | 119,580 | Common | Form 4 ↗ |
| Joseph Anthony Ferraro | SVP, General Counsel, CCO | 2024-10-18 | D | 320 | 60 | 19,190 | Common | Form 4 ↗ |
| Steven K. Barg | Director | 2024-10-30 | A | 4,663 | 0 | 0 | Common | Form 4 ↗ |
| Michael J. Barber | Director | 2024-10-30 | A | 4,663 | 0 | 0 | Common | Form 4 ↗ |
| Stephanie Okey | Director | 2024-10-30 | A | 4,663 | 0 | 0 | Common | Form 4 ↗ |
| J. Martin Carroll | Director | 2024-10-30 | A | 4,663 | 0 | 0 | Common | Form 4 ↗ |
| Gregory T. Lucier | Director | 2024-10-30 | A | 4,663 | 0 | 0 | Common | Form 4 ↗ |
| Rolf Classon | Director | 2024-10-30 | A | 4,663 | 0 | 0 | Common | Form 4 ↗ |
| Frank A. Damelio | Director | 2024-10-30 | A | 4,663 | 0 | 0 | Common | Form 4 ↗ |
| Jack Stahl | Director | 2024-10-30 | A | 4,663 | 0 | 0 | Common | Form 4 ↗ |
| Donald E. Morel Jr | Director | 2024-10-30 | A | 4,663 | 0 | 0 | Common | Form 4 ↗ |
| Michelle R. Ryan | Director | 2024-10-30 | A | 4,663 | 0 | 0 | Common | Form 4 ↗ |
| Michelle R. Ryan | Director | 2024-11-11 | D | 2,800 | 60 | 167,160 | Common | Form 4 ↗ |
| Michael J. Barber | Director | 2024-12-18 | D | 18,052 | — | — | Common | Form 4 ↗ |
| Michelle R. Ryan | Director | 2024-12-18 | D | 10,835 | — | — | Common | Form 4 ↗ |
| Ricky Hopson | Pres. BioProduct Delivery, CoS | 2024-12-18 | D | 10,669 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ricky Hopson | Pres. BioProduct Delivery, CoS | 2024-12-18 | D | 2,828 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ricky Hopson | Pres. BioProduct Delivery, CoS | 2024-12-18 | D | 2,565 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ricky Hopson | Pres. BioProduct Delivery, CoS | 2024-12-18 | D | 3,055 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ricky Hopson | Pres. BioProduct Delivery, CoS | 2024-12-18 | D | 3,650 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ricky Hopson | Pres. BioProduct Delivery, CoS | 2024-12-18 | D | 2,622 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ricky Hopson | Pres. BioProduct Delivery, CoS | 2024-12-18 | D | 1,550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ricky Hopson | Pres. BioProduct Delivery, CoS | 2024-12-18 | D | 10,722 | — | — | Common | Form 4 ↗ |
| Ricky Hopson | Pres. BioProduct Delivery, CoS | 2024-12-18 | A | 10,722 | 0 | 0 | Common | Form 4 ↗ |
| Ricky Hopson | Pres. BioProduct Delivery, CoS | 2024-12-18 | D | 29,974 | — | — | Common | Form 4 ↗ |
| Aristippos Gennadios | Group Pres. Pharma & Consumer | 2024-12-18 | D | 21,562 | — | — | Common | Form 4 ↗ |
| Aristippos Gennadios | Group Pres. Pharma & Consumer | 2024-12-18 | A | 21,562 | 0 | 0 | Common | Form 4 ↗ |
| Alessandro Maselli | Director | 2024-12-18 | D | 44,427 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alessandro Maselli | Director | 2024-12-18 | D | 15,568 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alessandro Maselli | Director | 2024-12-18 | D | 15,395 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alessandro Maselli | Director | 2024-12-18 | D | 13,735 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alessandro Maselli | Director | 2024-12-18 | D | 10,523 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alessandro Maselli | Director | 2024-12-18 | D | 10,375 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alessandro Maselli | Director | 2024-12-18 | D | 11,093 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alessandro Maselli | Director | 2024-12-18 | D | 113,224 | — | — | Common | Form 4 ↗ |
| Alessandro Maselli | Director | 2024-12-18 | D | 177,521 | — | — | Common | Form 4 ↗ |
| J. Martin Carroll | Director | 2024-12-18 | D | 32,734 | — | — | Common | Form 4 ↗ |
| Gregory T. Lucier | Director | 2024-12-18 | D | 36,914 | — | — | Common | Form 4 ↗ |
| Rolf Classon | Director | 2024-12-18 | D | 47,984 | — | — | Common | Form 4 ↗ |
| Frank A. Damelio | Director | 2024-12-18 | D | 12,635 | — | — | Common | Form 4 ↗ |
| Jack Stahl | Director | 2024-12-18 | D | 47,984 | — | — | Common | Form 4 ↗ |
| Steven K. Barg | Director | 2024-12-18 | D | 12,374 | — | — | Common | Form 4 ↗ |
| Aristippos Gennadios | Group Pres. Pharma & Consumer | 2024-12-18 | D | 113,724 | — | — | Common | Form 4 ↗ |
| Stephanie Okey | Director | 2024-12-18 | D | 12,635 | — | — | Common | Form 4 ↗ |
| Donald E. Morel Jr | Director | 2024-12-18 | D | 70,118 | — | — | Common | Form 4 ↗ |
| John J. Greisch | Director | 2024-12-18 | D | 127,096 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John J. Greisch | Director | 2024-12-18 | D | 33,530 | — | — | Common | Form 4 ↗ |
| John J. Greisch | Director | 2024-12-18 | A | 33,530 | 0 | 0 | Common | Form 4 ↗ |
| John J. Greisch | Director | 2024-12-18 | D | 34,000 | — | — | Common | Form 4 ↗ |
| John J. Greisch | Director | 2024-12-18 | D | 79,932 | — | — | Common | Form 4 ↗ |
| Lisa Evoli | SVP, Chief HR Officer | 2024-12-18 | D | 14,225 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lisa Evoli | SVP, Chief HR Officer | 2024-12-18 | D | 12,032 | — | — | Common | Form 4 ↗ |
| Lisa Evoli | SVP, Chief HR Officer | 2024-12-18 | A | 12,032 | 0 | 0 | Common | Form 4 ↗ |
| Lisa Evoli | SVP, Chief HR Officer | 2024-12-18 | D | 39,366 | — | — | Common | Form 4 ↗ |
| Matti Masanovich | SVP, Chief Financial Officer | 2024-12-18 | D | 81,082 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matti Masanovich | SVP, Chief Financial Officer | 2024-12-18 | D | 71,691 | — | — | Common | Form 4 ↗ |
| Matti Masanovich | SVP, Chief Financial Officer | 2024-12-18 | A | 71,691 | 0 | 0 | Common | Form 4 ↗ |
| Matti Masanovich | SVP, Chief Financial Officer | 2024-12-18 | D | 76,475 | — | — | Common | Form 4 ↗ |
| Alessandro Maselli | Director | 2024-12-18 | D | 103,360 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alessandro Maselli | Director | 2024-12-18 | A | 113,224 | 0 | 0 | Common | Form 4 ↗ |
| Joseph Anthony Ferraro | SVP, General Counsel, CCO | 2024-12-18 | D | 14,265 | — | — | Common | Form 4 ↗ |
| Joseph Anthony Ferraro | SVP, General Counsel, CCO | 2024-12-18 | A | 14,265 | 0 | 0 | Common | Form 4 ↗ |
| Joseph Anthony Ferraro | SVP, General Counsel, CCO | 2024-12-18 | D | 23,967 | — | — | Common | Form 4 ↗ |
| Scott Gunther | SVP, Quality & Reg. Affairs | 2024-12-18 | D | 12,938 | — | — | Common | Form 4 ↗ |
| Scott Gunther | SVP, Quality & Reg. Affairs | 2024-12-18 | A | 12,938 | 0 | 0 | Common | Form 4 ↗ |
| Scott Gunther | SVP, Quality & Reg. Affairs | 2024-12-18 | D | 39,635 | — | — | Common | Form 4 ↗ |
| Michael Hatzfeld | Chief Accounting Officer | 2024-12-18 | D | 3,144 | — | — | Common | Form 4 ↗ |
| Michael Hatzfeld | Chief Accounting Officer | 2024-12-18 | A | 3,144 | 0 | 0 | Common | Form 4 ↗ |
| Michael Hatzfeld | Chief Accounting Officer | 2024-12-18 | D | 13,532 | — | — | Common | Form 4 ↗ |
| David McErlane | Group President, Biologics | 2024-12-18 | D | 14,740 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David McErlane | Group President, Biologics | 2024-12-18 | D | 11,426 | — | — | Common | Form 4 ↗ |
| David McErlane | Group President, Biologics | 2024-12-18 | A | 11,426 | 0 | 0 | Common | Form 4 ↗ |
| David McErlane | Group President, Biologics | 2024-12-18 | D | 36,304 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Thomas Castellano | PSU | 2022-07-26 | 1,579 | 3,158 | — | 4,737 | $312,516 |
| Ricky Hopson | RSU | 2022-07-26 | — | — | 651 | — | 70,067 |
| Steven Fasman | RSU | 2022-07-26 | — | — | 2,788 | — | 300,072 |
| Aristippos Gennadios | OPTION | 2022-07-26 | — | — | 8,078 | — | 300,017 |
| John Chiminski | RSU | 2022-07-26 | — | — | 37,165 | — | 4,000,069 |
| Manja Boerman | PSU | 2022-07-26 | 822 | 1,643 | — | 2,465 | 162,591 |
| Aristippos Gennadios | PSU | 2022-07-26 | 1,264 | 2,527 | — | 3,791 | 250,072 |
| Manja Boerman | PSU | 2022-07-26 | 755 | 1,510 | — | 3,020 | 162,521 |
| Alessandro Maselli | RSU | 2022-07-26 | — | — | 10,221 | — | 1,100,086 |
| Ricky Hopson | OPTION | 2022-07-26 | — | — | 2,828 | — | 105,032 |
| Ricky Hopson | PSU | 2022-07-26 | 407 | 813 | — | 1,626 | 87,503 |
| Steven Fasman | PSU | 2022-07-26 | 1,743 | 3,485 | — | 6,970 | 375,091 |
| Aristippos Gennadios | RSU | 2022-07-01 | — | — | 18,689 | — | 2,000,097 |
| Aristippos Gennadios | PSU | 2022-07-26 | 1,162 | 2,323 | — | 4,646 | 250,024 |
| Manja Boerman | OPTION | 2022-07-26 | — | — | 5,251 | — | 195,022 |
| Manja Boerman | PSU | 2022-07-26 | 9,292 | 18,583 | — | 37,166 | 2,000,088 |
| Thomas Castellano | RSU | 2022-07-26 | — | — | 2,323 | — | 250,024 |
| Steven Fasman | PSU | 2022-07-26 | 1,895 | 3,790 | — | 5,685 | 375,058 |
| Steven Fasman | OPTION | 2022-07-26 | — | — | 12,117 | — | 450,025 |
| Thomas Castellano | OPTION | 2022-07-26 | — | — | 10,097 | — | 375,003 |
| Alessandro Maselli | OPTION | 2022-07-26 | — | — | 44,427 | — | 1,650,019 |
| Thomas Castellano | PSU | 2022-07-26 | 1,452 | 2,904 | — | 5,808 | 312,558 |
| Alessandro Maselli | PSU | 2022-07-26 | 6,948 | 13,895 | — | 20,843 | 1,375,049 |
| Ricky Hopson | PSU | 2022-07-26 | 443 | 885 | — | 1,328 | 87,580 |
| Aristippos Gennadios | RSU | 2022-07-26 | — | — | 1,859 | — | 200,084 |
| Alessandro Maselli | PSU | 2022-07-26 | 6,388 | 12,776 | — | 25,552 | 1,375,081 |
| Manja Boerman | RSU | 2022-07-26 | — | — | 1,208 | — | 130,017 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Thomas Castellano | $250,024 | $625,074 | $375,003 | 50.0% |
| Ricky Hopson | 70,067 | 175,083 | 105,032 | 50.0% |
| Steven Fasman | 300,072 | 750,149 | 450,025 | 50.0% |
| Aristippos Gennadios | 2,200,181 | 500,096 | 300,017 | 16.7% |
| John Chiminski | 4,000,069 | 0 | 0 | 0.0% |
| Manja Boerman | 130,017 | 2,325,200 | 195,022 | 87.7% |
| Alessandro Maselli | 1,100,086 | 2,750,130 | 1,650,019 | 50.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ricky Hopson | PSU | 18,204 | — | $39,306 |
| Alessandro Maselli | PSU | 1,949 | — | 3,294 |
| Steven Fasman | RSU | 910,647 | — | 1,125,000 |
| Steven Fasman | RSU | 475,703 | — | 475,703 |
| Steven Fasman | RSU | 1,235,370 | — | 1,125,000 |
| Aristippos Gennadios | PSU | 6,155 | — | 4,934 |
| John Chiminski | RSU | 5,007,733 | — | 5,007,733 |
| Thomas Castellano | RSU | 1,000,012 | — | 1,690,045 |
| Steven Fasman | RSU | 1,125,000 | — | 1,125,000 |
| Alessandro Maselli | RSU | 3,761 | — | 6,356 |
| Manja Boerman | RSU | 900,000 | — | 1,521,022 |
| Ricky Hopson | RSU | 690,000 | — | 1,489,847 |
| Aristippos Gennadios | RSU | 1,575,572 | — | 1,100,000 |
| Aristippos Gennadios | RSU | 1,372,127 | — | 1,100,000 |
| Aristippos Gennadios | RSU | 1,100,000 | — | 881,843 |
| Ricky Hopson | RSU | 408,278 | — | 690,000 |
| Ricky Hopson | RSU | 319,563 | — | 690,000 |
| Aristippos Gennadios | RSU | 301,222 | — | 301,222 |
| Alessandro Maselli | RSU | 10,221 | — | 17,274 |
| Steven Fasman | PSU | 12,762 | — | 12,762 |
| Alessandro Maselli | PSU | 6,948 | — | 11,742 |
| Alessandro Maselli | PSU | 6,388 | — | 10,796 |
| Alessandro Maselli | RSU | 3,009 | — | 5,085 |
| Alessandro Maselli | RSU | 2,838 | — | 4,796 |
| Alessandro Maselli | Option | 7,699 | 88.1 | — |
| Alessandro Maselli | PSU | 1,881 | — | 3,179 |
| Alessandro Maselli | Option | 44,427 | 107.63 | — |
| Alessandro Maselli | Option | 11,676 | 113 | — |
| Alessandro Maselli | Option | 3,436 | 54.94 | — |
Our executive compensation program ties pay delivery to the successful execution of our overall business goals and adherence to our core values, which we believe best serves the interests of our shareholders. We seek to maintain a competitive program that ties a significant portion of executive pay to our financial and stock price performance to align executive interests with those of our shareholders on an annual and long-term basis.
| CEO STI target (% of salary) | 110% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Frederic W. Cook & Co., Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-01-25 | 152,656,995 | 4,216,702 | 485,008 | 97.01% | Passed |
| 2022 | 2022-10-27 | 156,798,263 | 7,319,365 | 336,040 | 95.34% | Passed |
| 2021 | 2021-10-28 | 156,030,416 | 5,100,577 | 30,355 | 96.83% | Passed |
| 2020 | 2020-10-29 | 159,906,907 | 3,335,249 | 150,492 | 97.87% | Passed |
| 2019 | 2019-10-30 | 149,390,967 | 1,941,030 | 166,190 | 98.61% | Passed |
| 2018 | 2018-10-31 | 129,379,863 | 4,072,327 | 165,605 | 96.95% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2024 | 2024-01-25 | 97.01%a |
| 2022 | 2022-10-27 | 95.34%b |
| 2021 | 2021-10-28 | 96.83%c |
a. Approved under the standard stated in the filing — “Majority in voting power of the shares present in person or represented by proxy and entitled to vote on the subject matter. | Abstentions: Abstentions will have the effect of a vote against. Broker non-votes will have no effect on the outcome.”.
b. Approved under the standard stated in the filing — “Majority in voting power of the shares present in person or represented by proxy and entitled to vote on the matter. | Abstentions: Abstentions will have the effect of a vote against. Broker non-votes will have no effect on the outcome.”.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| J. Martin CarrollIndependent · Lead Independent Director · Compensation and Leadership · Nominating and Corporate Governance · Quality and Regulatory Compliance (Chair) | $151,401 | $274,954 | $0 | — | $0 | $426,355 |
| John J. GreischNot independent · Board Chair · Strategic and Operational Review (Chair) | 125,907 | 274,954 | 0 | — | 0 | 400,861 |
| Jack StahlIndependent · Audit (Chair) | 120,151 | 274,954 | 0 | — | 0 | 395,105 |
| Gregory T. LucierIndependent · Audit · Compensation and Leadership (Chair) | 112,651 | 274,954 | 0 | — | 0 | 387,605 |
| Donald E. Morel JrIndependent · Quality and Regulatory Compliance | 110,000 | 274,954 | 0 | — | 0 | 384,954 |
| Rosemary A. CraneIndependent · Audit | 110,000 | 274,954 | 0 | — | 0 | 384,954 |
| Rolf ClassonIndependent · Audit · Compensation and Leadership · Nominating and Corporate Governance (Chair) | 110,000 | 274,954 | 0 | — | 0 | 384,954 |
| Christa KreuzburgIndependent · Strategic and Operational Review | 100,151 | 274,954 | 0 | — | 0 | 375,105 |
| Madhavan BalachandranIndependent · Compensation and Leadership | 100,000 | 274,954 | 0 | — | 0 | 374,954 |
| Michael J. BarberIndependent · Compensation and Leadership · Nominating and Corporate Governance | 100,000 | 274,954 | 0 | — | 0 | 374,954 |
| Karen FlynnNot independent | 60,440 | 296,818 | 0 | — | 0 | 357,258 |
| Peter ZippeliusNot independent · Departed during FY | 58,611 | 274,954 | 0 | — | 0 | 333,565 |
| Alessandro MaselliEmployee director | 0 | 0 | 0 | — | 158,437 | 158,437 |
| John ChiminskiEmployee director · Departed during FY | 0 | 0 | 0 | — | 107,698 | 107,698 |
| Steven K. BargIndependent · Quality and Regulatory Compliance · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
| Frank A. D'AmelioNewly elected | 0 | 0 | 0 | — | 0 | 0 |
| Stephanie OkeyIndependent · Compensation and Leadership · Nominating and Corporate Governance · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
| Michelle R. RyanIndependent · Audit · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $100,000 |
|---|---|
| Annual equity retainer | $275,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 12,500 / 10,000 |
| Stock ownership guideline | $5 |
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $1,259,312 |
| Equity awards (grant-date value) | $3,321,312 |
| All other compensation | $266,135 |
| Total cost of the board | $4,846,759 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Catalent names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Catalent.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Incyte Corporation | 2025 | William Meury | $647,260 | $27,509,657 | $2,573,998 | $1,300,000 | $32,085,952 |
| 2 | Biogen Inc. | 2025 | Christopher Viehbacher | 1,727,885 | 18,368,875 | 0 | 3,190,875 | 23,646,004 |
| 3 | Boston Scientific Corporation | 2025 | Michael Mahoney | 1,442,603 | 13,608,056 | 3,749,980 | 4,002,001 | 23,532,050 |
| 4 | Vertex Pharmaceuticals Incorporated | 2025 | Reshma Kewalramani | 1,600,000 | 15,002,270 | 0 | 4,118,640 | 21,144,261 |
| 5 | Horizon Pharma plc | 2022 | Timothy Walbert | 1,292,727 | 16,601,305 | 0 | 0 | 20,103,869 |
| 6 | Align Technology, Inc. | 2025 | Joseph Hogan | 1,400,000 | 16,556,872 | 0 | 1,220,100 | 19,193,988 |
| 7 | Jazz Pharmaceuticals plc | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 8 | The Cooper Companies, Inc. | 2025 | Albert White III | 1,170,769 | 6,642,918 | 6,643,050 | 1,525,951 | 16,051,141 |
| 9 | Hologic, Inc. | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 10 | Agilent Technologies, Inc. | 2025 | Padraig McDonnell | 1,141,345 | 8,169,850 | 2,017,759 | 1,436,809 | 12,827,236 |
| 11 | STERIS plc | 2026 | Daniel Carestio | 1,095,707 | 4,333,951 | 4,334,251 | 1,725,007 | 11,508,522 |
| 12 | Perrigo plc | 2025 | Patrick Lockwood-Taylor | 1,223,333 | 6,990,564 | 0 | 687,250 | 9,042,603 |
| 13 | Bio-Rad Laboratories, Inc. | 2025 | Norman Schwartz | 1,089,877 | 4,856,574 | 1,458,975 | 562,088 | 7,995,841 |
| 14 | West Pharmaceutical Services, Inc. | 2025 | Eric Green | 1,177,290 | 3,327,048 | 1,108,961 | 1,471,613 | 7,190,876 |
| 15 | Mettler-Toledo International Inc. | 2025 | Patrick Kaltenbach | 1,145,999 | 3,267,808 | 1,635,033 | 462,984 | 6,741,212 |
| 16 | Catalent | 2023 | Alessandro Maselli | 925,000 | 3,850,216 | 1,650,019 | 0 | 6,583,672 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Catalent | 0% | PSU 50 · Option 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| Agilent Technologies, Inc. | not disclosed | PSU 60 · Options 20 · RSU 20 | No | Semler Brossy |
| Align Technology, Inc. | 58.1% | MSU 70 · RSU 30 | Yes — Relative Total Stockholder Return (TSR) vs. Nasdaq Composite Index | Compensia, Inc. |
| Bio-Rad Laboratories, Inc. | not disclosed | not disclosed | not disclosed | Compensia, Inc. |
| Biogen Inc. | 127% | PSU 60 · RSU 40 | Yes | Pay Governance |
| Boston Scientific Corporation | 173% | PSU 50 · RSU 25 · Options 25 | No | Semler Brossy Consulting Group, LLC |
| Hologic, Inc. | 109% | PSU 50 · RSU 25 · Option 25 | No | Pearl Meyer & Partners, LLC |
| Horizon Pharma plc | 100% | RSU 50 · PSU 50 | Yes — Relative TSR | Aon |
| Incyte Corporation | 138.6% | Performance Shares 60 · RSU 40 | Yes — relative total shareholder return (TSR) | Aon |
| Jazz Pharmaceuticals plc | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Mettler-Toledo International Inc. | not disclosed | not disclosed | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners |
| Perrigo plc | 44.3% | PSU 70 · RSU 30 | Yes — Relative TSR (rTSR) | FW Cook |
| STERIS plc | 125.1% | RSU 50 · Options 50 | not disclosed | Frederic W. Cook & Co., Inc. |
| The Cooper Companies, Inc. | 100.9% | Options 50 · PSU 50 | No | Compensia |
| Vertex Pharmaceuticals Incorporated | not disclosed | PSU 55 · RSU 45 | No | not disclosed |
| West Pharmaceutical Services, Inc. | 100% | PSU 50 · RSU 25 · Options 25 | No | Pay Governance |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Alessandro Maselli | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Summary Compensation Table”. As printed: 6,583,672. Filing ↗machine: r3 · c31 · span 1055835–1055844 |
| 2 | Section 01, John Chiminski | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Summary Compensation Table”. As printed: 4,807,767. Filing ↗machine: r23 · c31 · span 1123586–1123595 |
| 3 | Section 01, Manja Boerman | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Summary Compensation Table”. As printed: 3,979,888. Filing ↗machine: r27 · c31 · span 1138355–1138364 |
| 4 | Section 01, Aristippos Gennadios | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Summary Compensation Table”. As printed: 3,799,557. Filing ↗machine: r19 · c31 · span 1110488–1110497 |
| 5 | Section 01, Thomas Castellano | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Summary Compensation Table”. As printed: 2,729,983. Filing ↗machine: r7 · c31 · span 1070604–1070613 |
| 6 | Section 01, Steven Fasman | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Summary Compensation Table”. As printed: 2,310,299. Filing ↗machine: r15 · c31 · span 1095705–1095714 |
| 7 | Section 01, Ricky Hopson | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Summary Compensation Table”. As printed: 972,307. Filing ↗machine: r11 · c31 · span 1084097–1084104 |
| 8 | Section 03, Thomas Castellano PSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r12 · c26 · span 1298328–1298333 |
| 9 | Section 03, Ricky Hopson RSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r15 · c34 · span 1323257–1323260 |
| 10 | Section 03, Steven Fasman RSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r20 · c34 · span 1361508–1361513 |
| 11 | Section 03, Aristippos Gennadios OPTION | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r26 · c38 · span 1402500–1402505 |
| 12 | Section 03, John Chiminski RSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r31 · c34 · span 1440053–1440059 |
| 13 | Section 03, Manja Boerman PSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r36 · c27 · span 1477411–1477416 |
| 14 | Section 03, Aristippos Gennadios PSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r29 · c26 · span 1422393–1422398 |
| 15 | Section 03, Manja Boerman PSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r35 · c27 · span 1470064–1470069 |
| 16 | Section 03, Alessandro Maselli RSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r5 · c34 · span 1246799–1246805 |
| 17 | Section 03, Ricky Hopson OPTION | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r14 · c38 · span 1316614–1316619 |
| 18 | Section 03, Ricky Hopson PSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r16 · c26 · span 1329263–1329266 |
| 19 | Section 03, Steven Fasman PSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r21 · c26 · span 1367519–1367524 |
| 20 | Section 03, Aristippos Gennadios RSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r25 · c34 · span 1394559–1394565 |
| 21 | Section 03, Aristippos Gennadios PSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r28 · c26 · span 1415154–1415159 |
| 22 | Section 03, Manja Boerman OPTION | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r33 · c38 · span 1457192–1457197 |
| 23 | Section 03, Manja Boerman PSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r37 · c27 · span 1485927–1485933 |
| 24 | Section 03, Thomas Castellano RSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r10 · c34 · span 1285078–1285083 |
| 25 | Section 03, Steven Fasman PSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r22 · c26 · span 1374758–1374763 |
| 26 | Section 03, Steven Fasman OPTION | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r19 · c38 · span 1354864–1354870 |
| 27 | Section 03, Thomas Castellano OPTION | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r9 · c38 · span 1278434–1278440 |
| 28 | Section 03, Alessandro Maselli OPTION | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r4 · c38 · span 1240153–1240159 |
| 29 | Section 03, Thomas Castellano PSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r11 · c26 · span 1291089–1291094 |
| 30 | Section 03, Alessandro Maselli PSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r7 · c26 · span 1260056–1260062 |
| 31 | Section 03, Ricky Hopson PSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r17 · c26 · span 1336497–1336500 |
| 32 | Section 03, Aristippos Gennadios RSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r27 · c34 · span 1409143–1409148 |
| 33 | Section 03, Alessandro Maselli PSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r6 · c26 · span 1252813–1252819 |
| 34 | Section 03, Manja Boerman RSU | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t184 · r34 · c35 · span 1463945–1463950 |
| 35 | Section 08, J. Martin Carroll | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Director Compensation”. As printed: 426,355. Filing ↗machine: span 696869–696999 |
| 36 | Section 08, John J. Greisch | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Director Compensation”. As printed: 400,861. Filing ↗machine: span 706500–706630 |
| 37 | Section 08, Jack Stahl | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Director Compensation”. As printed: 395,105. Filing ↗machine: span 715988–716118 |
| 38 | Section 08, Gregory T. Lucier | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Director Compensation”. As printed: 387,605. Filing ↗machine: span 711251–711381 |
| 39 | Section 08, Donald E. Morel Jr | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Director Compensation”. As printed: 384,954. Filing ↗machine: span 713586–713716 |
| 40 | Section 08, Rosemary A. Crane | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Director Compensation”. As printed: 384,954. Filing ↗machine: span 701685–701815 |
| 41 | Section 08, Rolf Classon | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Director Compensation”. As printed: 384,954. Filing ↗machine: span 699276–699406 |
| 42 | Section 08, Christa Kreuzburg | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Director Compensation”. As printed: 375,105. Filing ↗machine: span 708832–708962 |
| 43 | Section 08, Madhavan Balachandran | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Director Compensation”. As printed: 374,954. Filing ↗machine: span 692128–692258 |
| 44 | Section 08, Michael J. Barber | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Director Compensation”. As printed: 374,954. Filing ↗machine: span 694537–694667 |
| 45 | Section 08, Karen Flynn | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Director Compensation”. As printed: 357,258. Filing ↗machine: span 704087–704217 |
| 46 | Section 08, Peter Zippelius | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Director Compensation”. As printed: 333,565. Filing ↗machine: span 718394–718524 |
| 47 | Section 08, Alessandro Maselli | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Director Compensation”. As printed: 158,437. Filing ↗ |
| 48 | Section 08, John Chiminski | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Director Compensation”. As printed: 107,698. Filing ↗ |
| 49 | Section 08, Steven K. Barg | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 50 | Section 08, Frank A. D'Amelio | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 51 | Section 08, Stephanie Okey | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 52 | Section 08, Michelle R. Ryan | DEF 14A | 2023-12-15 | 0001193125-23-295996 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 53 | Section 02, Michael Hatzfeld 2024-01-16 | Form 4 | 2024-01-18 | 0001596783-24-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Michael Hatzfeld 2024-01-16 | Form 4 | 2024-01-18 | 0001596783-24-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Michael Hatzfeld 2024-01-16 | Form 4 | 2024-01-18 | 0001596783-24-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Christa Kreuzburg 2024-01-25 | Form 4 | 2024-01-29 | 0001596783-24-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Scott Gunther 2024-03-15 | Form 4 | 2024-03-19 | 0001596783-24-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Ricky Hopson 2024-06-04 | Form 4 | 2024-06-05 | 0001596783-24-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Matti Masanovich 2024-07-08 | Form 4 | 2024-07-10 | 0001596783-24-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Ricky Hopson 2024-07-26 | Form 4 | 2024-07-30 | 0001596783-24-000049 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Aristippos Gennadios 2024-07-26 | Form 4 | 2024-07-30 | 0001596783-24-000045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Alessandro Maselli 2024-07-26 | Form 4 | 2024-07-30 | 0001596783-24-000052 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Scott Gunther 2024-07-26 | Form 4 | 2024-07-30 | 0001596783-24-000047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Matti Masanovich 2024-07-26 | Form 4 | 2024-07-30 | 0001596783-24-000054 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Lisa Evoli 2024-07-26 | Form 4 | 2024-07-30 | 0001596783-24-000056 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Joseph Anthony Ferraro 2024-07-26 | Form 4 | 2024-07-30 | 0001596783-24-000058 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, David McErlane 2024-07-26 | Form 4 | 2024-07-30 | 0001596783-24-000060 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Michael Hatzfeld 2024-07-26 | Form 4 | 2024-07-30 | 0001596783-24-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, John J. Greisch 2024-07-26 | Form 4 | 2024-07-30 | 0001596783-24-000064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Ricky Hopson 2024-07-29 | Form 4 | 2024-07-30 | 0001596783-24-000049 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Aristippos Gennadios 2024-07-29 | Form 4 | 2024-07-30 | 0001596783-24-000045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Alessandro Maselli 2024-07-29 | Form 4 | 2024-07-30 | 0001596783-24-000052 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Scott Gunther 2024-07-29 | Form 4 | 2024-07-30 | 0001596783-24-000047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Ricky Hopson 2024-08-02 | Form 4 | 2024-08-05 | 0001596783-24-000075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Aristippos Gennadios 2024-08-02 | Form 4 | 2024-08-05 | 0001596783-24-000066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Lisa Evoli 2024-08-02 | Form 4 | 2024-08-05 | 0001596783-24-000068 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Joseph Anthony Ferraro 2024-08-02 | Form 4 | 2024-08-05 | 0001596783-24-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Scott Gunther 2024-08-02 | Form 4 | 2024-08-05 | 0001596783-24-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, David McErlane 2024-09-26 | Form 4 | 2024-09-27 | 0001596783-24-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Joseph Anthony Ferraro 2024-10-18 | Form 4 | 2024-10-21 | 0001596783-24-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Steven K. Barg 2024-10-30 | Form 4 | 2024-11-01 | 0001596783-24-000113 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Michael J. Barber 2024-10-30 | Form 4 | 2024-11-01 | 0001596783-24-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Stephanie Okey 2024-10-30 | Form 4 | 2024-11-01 | 0001596783-24-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, J. Martin Carroll 2024-10-30 | Form 4 | 2024-11-01 | 0001596783-24-000101 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Gregory T. Lucier 2024-10-30 | Form 4 | 2024-11-01 | 0001596783-24-000099 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Rolf Classon 2024-10-30 | Form 4 | 2024-11-01 | 0001596783-24-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Frank A. Damelio 2024-10-30 | Form 4 | 2024-11-01 | 0001596783-24-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Jack Stahl 2024-10-30 | Form 4 | 2024-11-01 | 0001596783-24-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Donald E. Morel Jr 2024-10-30 | Form 4 | 2024-11-01 | 0001596783-24-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Michelle R. Ryan 2024-10-30 | Form 4 | 2024-11-01 | 0001596783-24-000111 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Michelle R. Ryan 2024-11-11 | Form 4 | 2024-11-14 | 0001596783-24-000122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Michael J. Barber 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137701 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Michelle R. Ryan 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137733 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Ricky Hopson 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137659 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Ricky Hopson 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137659 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Ricky Hopson 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137659 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Ricky Hopson 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137659 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Ricky Hopson 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137659 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Ricky Hopson 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137659 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Ricky Hopson 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137659 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Ricky Hopson 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137659 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Ricky Hopson 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137659 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Ricky Hopson 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137659 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Aristippos Gennadios 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137791 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Aristippos Gennadios 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137791 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Alessandro Maselli 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137660 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Alessandro Maselli 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137660 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Alessandro Maselli 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137660 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Alessandro Maselli 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137660 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Alessandro Maselli 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137660 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Alessandro Maselli 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137660 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Alessandro Maselli 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137660 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Alessandro Maselli 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137660 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Alessandro Maselli 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137660 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, J. Martin Carroll 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137708 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Gregory T. Lucier 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137720 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Rolf Classon 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137713 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Frank A. Damelio 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137717 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Jack Stahl 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137736 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Steven K. Barg 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137704 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Aristippos Gennadios 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137791 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Stephanie Okey 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137726 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Donald E. Morel Jr 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137723 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, John J. Greisch 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137657 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, John J. Greisch 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137657 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, John J. Greisch 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137657 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, John J. Greisch 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137657 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, John J. Greisch 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137657 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, Lisa Evoli 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137656 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Lisa Evoli 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137656 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Lisa Evoli 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137656 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Lisa Evoli 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137656 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, Matti Masanovich 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137658 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Matti Masanovich 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137658 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Matti Masanovich 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137658 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Matti Masanovich 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137658 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Alessandro Maselli 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137660 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Alessandro Maselli 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137660 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Joseph Anthony Ferraro 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137771 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Joseph Anthony Ferraro 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137771 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Joseph Anthony Ferraro 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137771 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Scott Gunther 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137780 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Scott Gunther 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137780 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Scott Gunther 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137780 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Michael Hatzfeld 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137784 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Michael Hatzfeld 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137784 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Michael Hatzfeld 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137784 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, David McErlane 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137787 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, David McErlane 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137787 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, David McErlane 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137787 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, David McErlane 2024-12-18 | Form 4 | 2024-12-18 | 0000950170-24-137787 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 06, 2024 vote | Form 8-K | 2024-01-26 | 0001193125-24-016202 | Item 5.07 · say-on-pay result. As reported: 97.01% (votes for as printed: 152,656,995). Filing ↗ |
| 153 | Section 06, 2022 vote | Form 8-K | 2022-11-01 | 0001596783-22-000182 | Item 5.07 · say-on-pay result. As reported: 95.34% (votes for as printed: 156,798,263). Filing ↗ |
| 154 | Section 06, 2021 vote | Form 8-K | 2021-11-02 | 0001596783-21-000180 | Item 5.07 · say-on-pay result. As reported: 96.83% (votes for as printed: 156,030,416). Filing ↗ |
| 155 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 156 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 157 | Section 09b board cost (computed) | Computed | — | — | Cash 1,259,312 + equity 3,321,312 + all other 266,135 = 4,846,759, summed across the director compensation table rows.machine: formula: Σ = 4,846,759 |
| 158 | Incyte Corporation, Section 10b CEO total | DEF 14A | 2026-04-28 | 0000879169-26-000031 | CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 159 | Biogen Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187303 | CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391 |
| 160 | Boston Scientific Corporation, Section 10b CEO total | DEF 14A | 2026-03-18 | 0000885725-26-000025 | CEO total compensation as printed in Boston Scientific Corporation's own proxy. As printed: 23,532,050. Filing ↗machine: r2 · c27 · span 1249807–1249817 |
| 161 | Vertex Pharmaceuticals Incorporated, Section 10b CEO total | DEF 14A | 2026-04-02 | 0000875320-26-000153 | CEO total compensation as printed in Vertex Pharmaceuticals Incorporated's own proxy. As printed: 21,144,261. Filing ↗machine: r2 · c13 · span 2942799–2942809 |
| 162 | Horizon Pharma plc, Section 10b CEO total | DEF 14A | 2023-06-30 | 0001193125-23-180318 | CEO total compensation as printed in Horizon Pharma plc's own proxy. As printed: 20,103,869. Filing ↗machine: span 746414–746424 |
| 163 | Align Technology, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001097149-26-000023 | CEO total compensation as printed in Align Technology, Inc.'s own proxy. As printed: 19,193,988. Filing ↗machine: r2 · c42 · span 933168–933178 |
| 164 | Jazz Pharmaceuticals plc, Section 10b CEO total | DEF 14A | 2026-06-08 | 0001232524-26-000029 | CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379 |
| 165 | The Cooper Companies, Inc., Section 10b CEO total | DEF 14A | 2026-02-24 | 0001628280-26-011110 | CEO total compensation as printed in The Cooper Companies, Inc.'s own proxy. As printed: 16,051,141. Filing ↗machine: t120 · r3 · c14 · span 744904–744914 |
| 166 | Hologic, Inc., Section 10b CEO total | DEF 14A | 2025-01-16 | 0001140361-25-001287 | CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. Filing ↗machine: r2 · c25 · span 1549664–1549674 |
| 167 | Agilent Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-02-06 | 0001193125-26-040286 | CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992 |
| 168 | STERIS plc, Section 10b CEO total | DEF 14A | 2026-06-11 | 0001193125-26-267599 | CEO total compensation as printed in STERIS plc's own proxy. As printed: 11,508,522. Filing ↗machine: t172 · r6 · c34 · span 820590–820600 |
| 169 | Perrigo plc, Section 10b CEO total | DEF 14A | 2026-03-20 | 0001585364-26-000024 | CEO total compensation as printed in Perrigo plc's own proxy. As printed: 9,042,603. Filing ↗machine: r3 · c12 · span 2143273–2143282 |
| 170 | Bio-Rad Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0000012208-26-000020 | CEO total compensation as printed in Bio-Rad Laboratories, Inc.'s own proxy. As printed: 7,995,841. Filing ↗machine: r2 · c24 · span 654200–654209 |
| 171 | West Pharmaceutical Services, Inc., Section 10b CEO total | DEF 14A | 2026-03-12 | 0001104659-26-026778 | CEO total compensation as printed in West Pharmaceutical Services, Inc.'s own proxy. As printed: 7,190,876. Filing ↗machine: t165 · r7 · c18 · span 1241781–1241790 |
| 172 | Mettler-Toledo International Inc., Section 10b CEO total | DEF 14A | 2026-03-18 | 0001174947-26-000389 | CEO total compensation as printed in Mettler-Toledo International Inc.'s own proxy. As printed: 6,741,212. Filing ↗machine: r2 · c7 · span 643529–643538 |
| 173 | Catalent (subject), Section 10b CEO total | DEF 14A | 2023-12-15 | 0001193125-23-295996 | CEO total compensation as printed in Catalent's own proxy. As printed: 6,583,672. Filing ↗machine: r3 · c31 · span 1055835–1055844 |
| 174 | Section 10a, STERIS plc reciprocity | DEF 14A | — | 0001193125-26-267599 | STERIS plc's most recent proxy was read; its disclosed peer group does not include Catalent. Filing ↗ |
| 175 | Section 10a, Jazz Pharmaceuticals plc reciprocity | DEF 14A | — | 0001232524-26-000029 | Jazz Pharmaceuticals plc's most recent proxy was read; its disclosed peer group does not include Catalent. Filing ↗ |
| 176 | Section 10a, Perrigo plc reciprocity | DEF 14A | — | 0001585364-26-000024 | Perrigo plc's most recent proxy was read; its disclosed peer group does not include Catalent. Filing ↗ |
| 177 | Section 10a, Agilent Technologies, Inc. reciprocity | DEF 14A | — | 0001193125-26-040286 | Agilent Technologies, Inc. names Catalent in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 178 | Section 10a, Boston Scientific Corporation reciprocity | DEF 14A | — | 0000885725-26-000025 | Boston Scientific Corporation's most recent proxy was read; its disclosed peer group does not include Catalent. Filing ↗ |
| 179 | Section 10a, Hologic, Inc. reciprocity | DEF 14A | — | 0001140361-25-001287 | Hologic, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalent. Filing ↗ |
| 180 | Section 10a, Vertex Pharmaceuticals Incorporated reciprocity | DEF 14A | — | 0000875320-26-000153 | Vertex Pharmaceuticals Incorporated's most recent proxy was read; its disclosed peer group does not include Catalent. Filing ↗ |
| 181 | Section 10a, Align Technology, Inc. reciprocity | DEF 14A | — | 0001097149-26-000023 | Align Technology, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalent. Filing ↗ |
| 182 | Section 10a, The Cooper Companies, Inc. reciprocity | DEF 14A | — | 0001628280-26-011110 | The Cooper Companies, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalent. Filing ↗ |
| 183 | Section 10a, West Pharmaceutical Services, Inc. reciprocity | DEF 14A | — | 0001104659-26-026778 | West Pharmaceutical Services, Inc.'s most recent proxy was read; its disclosed peer group does not include Catalent. Filing ↗ |
| 184 | Section 10a, Horizon Pharma plc reciprocity | DEF 14A | — | 0001193125-23-180318 | Horizon Pharma plc's most recent proxy was read; its disclosed peer group does not include Catalent. Filing ↗ |
| 185 | Section 10a, Mettler-Toledo International Inc. reciprocity | DEF 14A | — | 0001174947-26-000389 | Mettler-Toledo International Inc.'s most recent proxy was read; its disclosed peer group does not include Catalent. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.